Search research articles
Contact Us
Filters
Showing results (11-20 of 28) with videos related to
Page
of 3
Sort By:
Medical Examiner (Philadelphia, Pa.)
|
December 20, 2023
Ship Fever at the Bellevue Hospital
D M Reese, C A Lee
Current Opinion in Oncology
|
June 7, 2000
An update on prostate cancer research
E J Small, D M Reese
Drugs
|
January 5, 2002
Treatment options in hormone-refractory prostate cancer: current and future approaches
K A Harris, D M Reese
Cancer
|
March 16, 2000
Infusional floxuridine-based therapy for patients with metastatic renal cell carcinoma
D M Reese, M Corry, E J Small
Seminars in Oncology
|
December 22, 1999
Hormone-refractory prostate cancer: an evolving standard of care
E J Small, D M Reese, N J Vogelzang
Investigational New Drugs
|
July 30, 1999
A phase II trial of irinotecan in hormone-refractory prostate cancer
D M Reese, S Tchekmedyian, Y Chapman, et al.
Seminars in Oncology
|
October 31, 2001
Docetaxel, estramustine, plus trastuzumab in patients with metastatic androgen-independent prostate cancer
E J Small, R Bok, D M Reese, et al.
Urology
|
August 8, 2001
Intermittent androgen deprivation: update of cycling characteristics in patients without clinically apparent metastatic prostate cancer
G D Grossfeld, U B Chaudhary, D M Reese, et al.
Urology
|
February 2, 2000
Potential role of nephrectomy in the treatment of metastatic renal cell carcinoma: a retrospective analysis
V S Tigrani, D M Reese, E J Small, et al.
American Journal of Clinical Oncology
|
August 26, 1998
Undetectable serum prostate-specific antigen associated with metastatic prostate cancer: a case report and review of the literature
A A Safa, D M Reese, D M Carter, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 28) with videos related to
Sort By:
Page
of 3
Medical Examiner (Philadelphia, Pa.)
|
December 20, 2023
Ship Fever at the Bellevue Hospital
D M Reese, C A Lee
Current Opinion in Oncology
|
June 7, 2000
An update on prostate cancer research
E J Small, D M Reese
Drugs
|
January 5, 2002
Treatment options in hormone-refractory prostate cancer: current and future approaches
K A Harris, D M Reese
Cancer
|
March 16, 2000
Infusional floxuridine-based therapy for patients with metastatic renal cell carcinoma
D M Reese, M Corry, E J Small
Seminars in Oncology
|
December 22, 1999
Hormone-refractory prostate cancer: an evolving standard of care
E J Small, D M Reese, N J Vogelzang
Investigational New Drugs
|
July 30, 1999
A phase II trial of irinotecan in hormone-refractory prostate cancer
D M Reese, S Tchekmedyian, Y Chapman, et al.
Seminars in Oncology
|
October 31, 2001
Docetaxel, estramustine, plus trastuzumab in patients with metastatic androgen-independent prostate cancer
E J Small, R Bok, D M Reese, et al.
Urology
|
August 8, 2001
Intermittent androgen deprivation: update of cycling characteristics in patients without clinically apparent metastatic prostate cancer
G D Grossfeld, U B Chaudhary, D M Reese, et al.
Urology
|
February 2, 2000
Potential role of nephrectomy in the treatment of metastatic renal cell carcinoma: a retrospective analysis
V S Tigrani, D M Reese, E J Small, et al.
American Journal of Clinical Oncology
|
August 26, 1998
Undetectable serum prostate-specific antigen associated with metastatic prostate cancer: a case report and review of the literature
A A Safa, D M Reese, D M Carter, et al.
Page
of 3